Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL COLD AND SINUS vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Temporary relief of sinus congestion and pressure,Temporary relief of nasal congestion,Temporary reduction of fever,Relief of minor aches and pains associated with the common cold or flu
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.
Intravenous: 500 mg every 6 hours.
Ibuprofen: 2-4 hours (terminal; rapid elimination, no accumulation with intermittent use). Pseudoephedrine: 4-8 hours (terminal; prolonged in alkaline urine, up to 16 hours at p H 8).
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Pseudoephedrine is partially metabolized in the liver by N-demethylation.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Renal excretion of unchanged drug and metabolites: ibuprofen ~45-60% (primarily as conjugated metabolites, <10% unchanged), pseudoephedrine ~70-90% unchanged. Biliary/fecal elimination accounts for <10% for both components.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
Ibuprofen: ~99% primarily to albumin. Pseudoephedrine: negligible (<10% bound to plasma proteins).
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
Ibuprofen: 0.1-0.2 L/kg (low Vd, indicating limited tissue distribution). Pseudoephedrine: 2.5-3.5 L/kg (high Vd, extensive tissue distribution including CNS).
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral: ibuprofen ~80-100% (rapidly absorbed, no significant first-pass). Pseudoephedrine ~100% (well absorbed, minimal first-pass metabolism).
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
GFR 30-89 m L/min: Use lowest effective dose for shortest duration; monitor renal function. GFR <30 m L/min or dialysis: Contraindicated.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh Class A: No adjustment; use with caution. Child-Pugh Class B or C: Avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Children <12 years: Do not use. Children ≥12 years: Same as adult dosing; 1-2 tablets every 4-6 hours as needed; maximum 6 tablets in 24 hours.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Use lowest effective dose for shortest duration; avoid chronic use. Reduce initial dose to 1 tablet every 6-8 hours due to increased risk of renal impairment, GI bleeding, and cardiovascular events.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
None
Cardiovascular thrombotic events, gastrointestinal bleeding/ulceration/perforation, hypertension, renal toxicity, serious skin reactions, anaphylactoid reactions, exacerbation of asthma, and drug interactions including with ACE inhibitors, diuretics, and lithium.
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Hypersensitivity to ibuprofen, aspirin, or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; patients with severe hypertension or coronary artery disease; patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs; concurrent use of other sympathomimetics; in the setting of CABG surgery.
None
Take with food or milk to reduce gastrointestinal irritation. Avoid alcohol consumption as it increases the risk of NSAID-related gastric ulcers and bleeding. High-sodium foods may exacerbate hypertension in patients sensitive to the pressor effects of pseudoephedrine.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.62) for any malformation and 1.86 (95% CI 1.32-2.62) for cardiac malformations. Second trimester: Risk of oligohydramnios and premature closure of ductus arteriosus after 20 weeks. Third trimester: Avoid after 30 weeks due to risk of premature ductus arteriosus closure and oligohydramnios; after 32 weeks, increased risk of necrotizing enterocolitis, intracranial hemorrhage, and renal impairment in neonate (renal agenesis/dysgenesis). Pseudoephedrine: First trimester – possible increased risk of gastroschisis (odds ratio 1.8, 95% CI 1.0-3.2) and small intestinal atresia. Second and third trimesters: potential uteroplacental vasoconstriction leading to fetal hypoxia; risk of prematurity and low birth weight.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Ibuprofen: M/P ratio 0.005–0.006; low transfer into breast milk; AAP compatible; theoretical risk of platelet dysfunction in neonate. Pseudoephedrine: M/P ratio 2.6–3.5 (concentrated in milk); estimated infant dose 4.3% of maternal weight-adjusted dose; may cause irritability and sleep disturbances in infant; may reduce milk production by up to 24%. Caution advised; avoid in lactation if possible.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
Ibuprofen: No dose adjustment required; however, use lowest effective dose and shortest duration; avoid after 30 weeks gestation. Pseudoephedrine: No specific dose adjustment recommended based on pharmacokinetic changes, but use with caution due to vasoconstrictive effects; reduced efficacy may be observed due to increased plasma volume and renal clearance.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
Advil Cold and Sinus is a fixed-dose combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen inhibits COX-1/2, reducing prostaglandin synthesis, while pseudoephedrine is an α-adrenergic agonist causing vasoconstriction in nasal mucosa. Use cautiously in patients with hypertension, cardiovascular disease, or renal impairment due to pseudoephedrine's pressor effects and ibuprofen's potential to reduce renal blood flow and antagonize antihypertensives. Avoid in patients with severe coronary artery disease, uncontrolled hypertension, or concurrent MAOI use. Max duration: 3 days for sinus symptoms, 5 days for pain. Monitor for NSAID-induced GI bleeding, especially in elderly or those on anticoagulants/aspirin.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Do not take more than directed; do not exceed 6 caplets in 24 hours.,Avoid use with other products containing ibuprofen or other NSAIDs, including aspirin, to prevent overdose and serious side effects.,Discontinue use and seek medical attention if symptoms worsen, persist >3 days for sinus or >5 days for pain, or if new symptoms occur.,Take with food or milk to reduce stomach upset; avoid alcohol to lower risk of GI bleeding.,If you have high blood pressure, heart disease, thyroid disease, diabetes, or difficulty urinating due to prostate enlargement, consult a doctor before use.,Do not use if you are taking a prescription monoamine oxidase inhibitor (MAOI) or for 2 weeks after stopping an MAOI drug.,Pregnant or breastfeeding women should not use this product; ibuprofen is contraindicated in third trimester due to risk of premature closure of ductus arteriosus.,Store at room temperature away from moisture and heat.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL COLD AND SINUS vs AMVAZ, answered by our medical review team.
ADVIL COLD AND SINUS is a NSAID/Decongestant Combination that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL COLD AND SINUS and AMVAZ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL COLD AND SINUS is: 1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL COLD AND SINUS and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL COLD AND SINUS is classified as Category C. First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.